Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15985060 | 0.85 | MAPT (0.42) | MAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL17962159 | 0.81 | ALDH1A1 (0.34) | MEN1PSMD14PRKACACASP6KMT2A | |
| SCHEMBL23089302 | 0.78 | CPT2 (0.35) | LMNAIRAK4PKM | |
| SCHEMBL15972208 | 0.75 | INPPL1 (0.34) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL23122347 | 0.73 | MAPT (0.43) | CASP6POLBTDP1L3MBTL1MAPK1 | |
| SCHEMBL15972013 | 0.71 | ALDH1A1 (0.49) | POLBTDP1MAPK1ALDH1A1MAPT | |
| SCHEMBL15972015 | 0.71 | ALDH1A1 (0.49) | POLBTDP1MAPK1ALDH1A1MAPT | |
| SCHEMBL23705522 | 0.70 | KDM4E (0.40) | ALDH1A1 | |
| SCHEMBL15985110 | 0.68 | GRM1 (0.50) | ALDH1A1MAPTLMNA | |
| SCHEMBL13490403 | 0.68 | CHRM1 (0.45) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856252-B2 | 2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2018-01-02 | — | — | US | disclosed |
| EP-2958898-B1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2017-07-19 | — | — | EP | disclosed |
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | CANCER THERAPEUTICS CRC PTY LTD (AU) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222005-A1 | 2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE | B2M, HBG2, BCAT2 | MEN1 2210/4885PSMD14 2036/4885PRKACA 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.